Skyhawk Therapeutics

Biotech · Private

Small molecule drugs that modify RNA splicing to treat neurological and rare diseases

skyhawktx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
14 granted · 26 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2509GENEDIT INC——
2510DUO ONCOLOGY INC—$4.2M
2511Synthekine——
2512Skyhawk Therapeutics——
2513Nouscom——
2514Somite AI——
2515Alligator Bioscience AB (publ)—$10M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 14 granted of 40
  • Methods And Compositions For Modulating Splicinggranted
  • Compositions Useful For Modulating Splicingapplication
  • Methods And Compositions For Modulating Splicinggranted
  • Compositions Useful For Modulating Splicingapplication
  • Methods And Compositions For Modulating Splicinggranted
  • Compositions Useful For Modulating Splicingapplication
  • Compositions Useful For Modulating Splicingapplication
  • Compositions Useful For Modulating Splicingapplication
  • Compositions Useful For Modulating Splicingapplication
  • Compositions Useful For Modulating Splicingapplication
  • Compositions Useful For Modulating Splicingapplication
  • Compositions Useful For Modulating Splicingapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.